Arrowhead Pharmaceuticals, Inc.
Fully enroll Phase 3 studies of plozasiran in severe hypertriglyceridemia
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- 23 Jun 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025”
What we found
Evidence strength A What the grades mean
Arrowhead announced on June 23, 2025 that it completed enrollment in the Phase 3 SHASTA-3, SHASTA-4, and MUIR-3 studies for severe hypertriglyceridemia, well before the 2025 deadline.
-
A ARROWHEAD PHARMACEUTICALS, INC. - Form S-3ASR - FY2025 SEC filing confirms SHASTA-3, SHASTA-4, and SHASTA-5 have been fully enrolled
-
A ARROWHEAD PHARMACEUTICALS, INC. - Form 8-K - FY2025 SEC 8-K confirms completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3
-
D Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran Company press release announcing completed Phase 3 enrollment for sHTG studies
Checked 16 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Fully
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Arrowhead Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-ARWR-000414 · Corrections policy